The frequencies of lung metastasis, mutations in TP53, NRAS, and EGFR, the level of tumor markers (CEA and CA19‐9), and sum of the tumor diameter in patients with plasma KRAS mutation‐positive were higher compared to those in patients with KRAS mutation‐negative (Table S5). This evidence concerns the gene CEACAM5 and neoplasm.